Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience

被引：0

作者：

Seiwerth, Fran ^{[1
]}

Bitar, Lela ^{[1
]}

Markelic, Ivona ^{[1
]}

Dzubur, Fedza ^{[1
]}

Brcic, Luka ^{[2
]}

Seiwerth, Sven ^{[3
]}

Misic, Marija ^{[3
]}

Roglic, Mihovil ^{[1
]}

Plestina, Sanja ^{[1
]}

Cucevic, Branka ^{[1
]}

Kukulj, Suzana ^{[1
]}

Smojver-Jezek, Silvana ^{[1
]}

Samarzija, Miroslav ^{[1
]}

Jakopovic, Marko ^{[1
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Resp Dis Jordanovac, Zagreb, Croatia

[2] Med Univ Graz, Inst Pathol, Graz, Austria

[3] Univ Zagreb, Sch Med, Dept Pathol, Zagreb, Croatia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

EGFR;

D O I：

10.1016/j.jtho.2016.11.1782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-114

引用

页码：S1262 / S1262

页数：1

共 50 条

[1] Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients.
Zhao, Wei
Liu, Xingchen
Tian, Qing
Chang, Yan
Yang, Zhen
Chen, Liangan
BIOMEDICAL RESEARCH-INDIA, 2017, 28 (04): : 1917 - 1921
[2] Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma
Jokic, Vera
Savic-Vujovic, Katarina
Spasic, Jelena
Bukumiric, Zoran
Marinkovic, Mladen
Radosavljevic, Davorin
Cavic, Milena
DOSE-RESPONSE, 2022, 20 (03):
[3] The treatment of advanced lung adenocarcinoma with activating EGFR mutations
Rocco, Danilo
Della Gravara, Luigi
Battiloro, Ciro
Maione, Paolo
Gridelli, Cesare
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (18) : 2475 - 2482
[4] Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma
Kang, Hyo Jae
Lim, Hyo-Jeong
Park, Jong Sun
Cho, Young-Jae
Yoon, Ho-Il
Chung, Jin-Haeng
Lee, Jae Ho
Lee, Choon-Taek
RESPIRATORY MEDICINE, 2014, 108 (02) : 388 - 394
[5] Erlotinib Treatment in Patients with Advanced Lung Adenocarcinoma with CISH-positive and CISH-negative EGFR Gene Alterations
Hou, Ming-Mo
Huang, Shiu-Feng
Kuo, Han-Pin
Yang, Cheng-Ta
Tsai, Ying-Huang
Yu, Chih-Teng
Lin, Horng-Chyuan
Chen, Chih-Hung
Wang, Chih-Liang
Chung, Fu-Tsai
Hsieh, Jia-Juan
Hsu, Todd
Cheng, Hsin-Yi
Ou, Li-Ying
Wang, Hung-Ming
Lin, Yung-Chang
Chang, Nai-Jen
Chang, John Wen-Cheng
ANTICANCER RESEARCH, 2012, 32 (03) : 1107 - 1112
[6] EGFR MUTATION STATUS IN ADENOCARCINOMA LUNG: A SINGLE CENTRE EXPERIENCE FROM NORTHERN INDIA
Wadhwa, Jyoti
Jandya, Sunny
Batra, Sandeep
Sharma, Neelam
Sharma, Devender
Gupta, Atul
Puri, Rohit
Singh, Bhanu P.
Bali, San-Deep
Raina, Vimarsh
Vaid, Ashok K.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S606 - S606
[7] Retrospective Study About EGFR Mutations in Lung Cancer: Our Experience in a Spanish Hospital
Sanchez Cabrero, D.
Cruz, P.
Miranda, J.
Higuera, O.
Pertejo, A.
Ramon, J.
Torres, J. L.
Gutierrez, L.
Villamayor, J.
Vinal, D.
Esteban, I.
De Castro Carpeno, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1044 - S1044
[8] Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation
Cui, Yujie
Zhu, Tienian
Song, Xuejing
Liu, Jiankun
Liu, Shuang
Zhao, Ruijing
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (01) : 733 - 739
[9] Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
He, Yayi
Sun, Wenwen
Wang, Yan
Ren, Shengxiang
Li, Xuefei
Li, Jiayu
Rivard, Christopher J.
Zhou, Caicun
Hirsch, Fred R.
ONCOTARGETS AND THERAPY, 2016, 9 : 2409 - 2414
[10] Characterizing the secretome of EGFR mutant lung adenocarcinoma
Luu, Jennifer K.
Johnson, Fraser D.
Jajarmi, Jana
Sihota, Tianna
Shi, Rocky
Lu, Daniel
Farnsworth, Dylan
Spencer, Sandra E.
Negri, Gian Luca
Morin, Gregg B.
Lockwood, William W.
FRONTIERS IN ONCOLOGY, 2024, 13

← 1 2 3 4 5 →